The Goldman Sachs Group began coverage on shares of Geron (NASDAQ:GERN - Free Report) in a report published on Thursday morning, MarketBeat.com reports. The brokerage issued a sell rating and a $1.00 target price on the biopharmaceutical company's stock.
A number of other analysts have also issued reports on the company. HC Wainwright reaffirmed a "neutral" rating on shares of Geron in a research note on Wednesday, March 12th. Needham & Company LLC reissued a "buy" rating and set a $5.00 price objective on shares of Geron in a research note on Wednesday, March 12th. Finally, Scotiabank lowered Geron from a "sector outperform" rating to a "sector perform" rating and lowered their price objective for the stock from $4.00 to $1.50 in a research note on Thursday, May 8th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $4.61.
Check Out Our Latest Report on Geron
Geron Price Performance
Shares of NASDAQ:GERN traded down $0.06 during trading on Thursday, reaching $1.32. The stock had a trading volume of 7,539,580 shares, compared to its average volume of 11,275,306. The company has a debt-to-equity ratio of 0.44, a quick ratio of 6.97 and a current ratio of 7.87. The business has a fifty day moving average price of $1.43 and a 200-day moving average price of $1.93. The stock has a market cap of $840.73 million, a PE ratio of -6.29 and a beta of 0.64. Geron has a 1-year low of $1.17 and a 1-year high of $5.06.
Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.01. The firm had revenue of $39.60 million for the quarter, compared to analyst estimates of $49.88 million. Geron had a negative return on equity of 47.86% and a negative net margin of 119.54%. The business's revenue was up 12927.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.07) earnings per share. On average, equities analysts forecast that Geron will post -0.25 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Geron
A number of institutional investors and hedge funds have recently added to or reduced their stakes in GERN. Xponance Inc. lifted its stake in shares of Geron by 12.9% in the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company's stock valued at $150,000 after purchasing an additional 4,829 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in shares of Geron in the 4th quarter valued at $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Geron by 2.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company's stock valued at $627,000 after purchasing an additional 8,123 shares during the last quarter. Frisch Financial Group Inc. lifted its stake in shares of Geron by 84.3% in the 1st quarter. Frisch Financial Group Inc. now owns 19,025 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 8,700 shares during the last quarter. Finally, HighTower Advisors LLC lifted its stake in shares of Geron by 33.1% in the 4th quarter. HighTower Advisors LLC now owns 36,041 shares of the biopharmaceutical company's stock valued at $128,000 after purchasing an additional 8,967 shares during the last quarter. Institutional investors and hedge funds own 73.71% of the company's stock.
Geron Company Profile
(
Get Free Report)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
Recommended Stories

Before you consider Geron, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.
While Geron currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.